Peter DiLaura
Chief Executive Officer at Initial Therapeutics Inc
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mohamad Tabrizi | M | - |
ShangPharma Innovation, Inc.
 ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | 7 years |
| Cheng Zhang | M | - |
Character Biosciences, Inc.
 Character Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services The American company was founded by Nick Johnson, Cheng Zhang, and Marcel van der Brug, with Cheng Zhang serving as the CEO since incorporation. Character Biosciences is focused on developing therapies for ophthalmic and other progressive polygenic diseases. The company has developed a platform that integrates genomics with longitudinal clinical data to select drug targets and match therapies to the right patients. Currently, Character Biosciences is advancing two lead drug discovery programs through preclinical development for dry age-related macular degeneration. | - |
| Robert A. Drakas | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | 8 years |
| NIck Johnson | M | - |
Character Biosciences, Inc.
Character Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services The American company was founded by Nick Johnson, Cheng Zhang, and Marcel van der Brug, with Cheng Zhang serving as the CEO since incorporation. Character Biosciences is focused on developing therapies for ophthalmic and other progressive polygenic diseases. The company has developed a platform that integrates genomics with longitudinal clinical data to select drug targets and match therapies to the right patients. Currently, Character Biosciences is advancing two lead drug discovery programs through preclinical development for dry age-related macular degeneration. | - |
| Sander Duncan | M | - |
Lifeforce Capital Management, LLC
 Lifeforce Capital Management, LLC Investment ManagersFinance Lifeforce Capital Management, LLC (Lifeforce Capital) is a venture capital firm founded in 2015 by John Noonan. The firm is headquartered in Chevy Chase, Maryland. | 9 years |
| Rishi Sikka | M | - |
The Wharton School of the University of Pennsylvania
Lifeforce Capital Management, LLC
Lifeforce Capital Management, LLC Investment ManagersFinance Lifeforce Capital Management, LLC (Lifeforce Capital) is a venture capital firm founded in 2015 by John Noonan. The firm is headquartered in Chevy Chase, Maryland. | 7 years |
| Ya Jun Xu | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| John Noonan | M | - |
Lifeforce Capital Management, LLC
Lifeforce Capital Management, LLC Investment ManagersFinance Lifeforce Capital Management, LLC (Lifeforce Capital) is a venture capital firm founded in 2015 by John Noonan. The firm is headquartered in Chevy Chase, Maryland. | 10 years |
| Marcel van der Brug | M | - |
Character Biosciences, Inc.
Character Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services The American company was founded by Nick Johnson, Cheng Zhang, and Marcel van der Brug, with Cheng Zhang serving as the CEO since incorporation. Character Biosciences is focused on developing therapies for ophthalmic and other progressive polygenic diseases. The company has developed a platform that integrates genomics with longitudinal clinical data to select drug targets and match therapies to the right patients. Currently, Character Biosciences is advancing two lead drug discovery programs through preclinical development for dry age-related macular degeneration. | - |
| Juan-Carlos Lopez | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| Grant Green | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | 6 years |
| Jean Bidegainberry | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| Sarah Lively | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| Eric Parker | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| David Sahner | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| James H. Doudna Cate | M | - |
Initial Therapeutics Inc
 Initial Therapeutics Inc BiotechnologyHealth Technology Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY. | - |
| Rajesh Chopra | M | - |
Initial Therapeutics Inc
Initial Therapeutics Inc BiotechnologyHealth Technology Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY. | - |
| Charles Yang | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| Michael Ehlers | M | - |
Initial Therapeutics Inc
Initial Therapeutics Inc BiotechnologyHealth Technology Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY. | - |
| Spiros Liras | M | - |
Initial Therapeutics Inc
Initial Therapeutics Inc BiotechnologyHealth Technology Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY. | - |
| Rebecca Canter | F | - |
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | 6 years |
| Nathan Bays | M | - |
Lifeforce Capital Management, LLC
Lifeforce Capital Management, LLC Investment ManagersFinance Lifeforce Capital Management, LLC (Lifeforce Capital) is a venture capital firm founded in 2015 by John Noonan. The firm is headquartered in Chevy Chase, Maryland. | - |
| Ruth McKernan | M | 66 |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | 6 years |
| Seth Harrison | M | 63 |
Initial Therapeutics Inc
Initial Therapeutics Inc BiotechnologyHealth Technology Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY. | - |
| Stephen Munk | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| Carole Nüchterlein | F | 62 |
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | 8 years |
| Vivek Garipalli | M | 45 |
Character Biosciences, Inc.
Character Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services The American company was founded by Nick Johnson, Cheng Zhang, and Marcel van der Brug, with Cheng Zhang serving as the CEO since incorporation. Character Biosciences is focused on developing therapies for ophthalmic and other progressive polygenic diseases. The company has developed a platform that integrates genomics with longitudinal clinical data to select drug targets and match therapies to the right patients. Currently, Character Biosciences is advancing two lead drug discovery programs through preclinical development for dry age-related macular degeneration. | - |
| Kevin Pojasek | M | - |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | 6 years |
| Olivia Mitchell | F | 71 |
The Wharton School of the University of Pennsylvania
| 31 years |
| Krishna Kodukula | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| David Spellmeyer | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | 7 years |
| Xin Hui | M | 53 |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| Joel Dudley | M | - |
Character Biosciences, Inc.
Character Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services The American company was founded by Nick Johnson, Cheng Zhang, and Marcel van der Brug, with Cheng Zhang serving as the CEO since incorporation. Character Biosciences is focused on developing therapies for ophthalmic and other progressive polygenic diseases. The company has developed a platform that integrates genomics with longitudinal clinical data to select drug targets and match therapies to the right patients. Currently, Character Biosciences is advancing two lead drug discovery programs through preclinical development for dry age-related macular degeneration. | 2 years |
| Dirk Brockstedt | M | 55 |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| Michael Ehlers | M | - |
Initial Therapeutics Inc
Initial Therapeutics Inc BiotechnologyHealth Technology Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY. | - |
| Christian Billy Jung | M | 42 |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | 5 years |
| Ravi Kiron | M | 64 |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | 7 years |
| Giles Platford | M | - | 7 years | |
| Robert Wild | M | 53 |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | 7 years |
| Robert Lutz | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Karim Dabbagh | M | - |
Second Genome, Inc.
Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | 9 years |
| Yasuchika Hasegawa | M | 78 | 47 years | |
| David Perry | M | 56 |
Ventro Corp.
 Ventro Corp. Information Technology ServicesTechnology Services Ventro Corp. provides e-commerce solutions. | 4 years |
| Phil Bronner | M | 53 |
The Wharton School of the University of Pennsylvania
| 3 years |
| Rolando Gutíerrez-Esteinou | M | 63 | 1 years | |
| Matthew Young | M | 54 |
The Wharton School of the University of Pennsylvania
| 5 years |
| Shinji Honda | M | 66 | 36 years | |
| Justin Warren Slatky | M | - |
The Wharton School of the University of Pennsylvania
| 5 years |
| Bryce Markus | M | - |
The Wharton School of the University of Pennsylvania
| 5 years |
| Fumio Sudo | M | 83 | 6 years | |
| Maja M. Gross | F | - |
The Wharton School of the University of Pennsylvania
| 6 years |
| Lawrence Berger | M | 52 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Donna M. Walsh | F | - |
The Wharton School of the University of Pennsylvania
| 14 years |
| Adam Blackman | M | - |
The Wharton School of the University of Pennsylvania
| 5 years |
| Andrew Pearson | M | 52 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Brian W. Sullivan | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Mitchell Resnick | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Luv Dinesh Parikh | M | 48 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Jeffrey Dyer | M | 65 |
The Wharton School of the University of Pennsylvania
| 6 years |
| Dawn Fitzpatrick | F | 54 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Kwok Fung Lam | M | 50 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Marla Blow | F | 53 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Roger Cozzi | M | 54 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Joseph P. Puglise | M | 53 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Jim Obsitnik | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Rong Rong Liu | F | 54 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Alan L. Leonard Felder | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Sharon Hodgson | F | 58 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Keith Alexander | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Bruce Curtis Crosby | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Christopher Thomas | M | 49 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Carman Wong | F | 51 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Maria Alejandra Herrera | F | 59 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Robert Bernard | M | 58 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Francisco Javier Rodríguez Heredia | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Kaihan Krippendorff | M | - |
The Wharton School of the University of Pennsylvania
| 5 years |
| Paul Jackson | M | 60 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Lawrence Robbins | M | 54 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Eric Filipek | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Geraldo Travaglia Filho | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Chris Pucillo | M | 56 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Weijian Shan | M | 70 |
The Wharton School of the University of Pennsylvania
| 6 years |
| Stockton Croft | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Alex Gorsky | M | 63 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Raj Gollamudi | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Julia Ossipov-Grodsky | F | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Aaron Martin | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Kosty Gilis | M | 50 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Allison Goldberg | F | 47 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Randall Bort | M | 60 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Marc A. Singer | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Christophe Charlier | M | 52 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Suresh Shanmugham | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Michael DeRosa | M | 52 |
The Wharton School of the University of Pennsylvania
| 2 years |
| R. Kenneth Bryant | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Kurt Ekert | M | 53 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Matthew Gustke | M | 50 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Rodd Macklin | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Larry Spyros Antonatos | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Andrie Setiawan Yapsir | M | 64 |
The Wharton School of the University of Pennsylvania
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 91 | 91.00% |
| Japan | 5 | 5.00% |
| United Kingdom | 4 | 4.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Peter DiLaura
- Personal Network
